IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v117y2014i3p311-327.html
   My bibliography  Save this article

Does deregulation in community pharmacy impact accessibility of medicines, quality of pharmacy services and costs? Evidence from nine European countries

Author

Listed:
  • Vogler, Sabine
  • Habimana, Katharina
  • Arts, Danielle

Abstract

To analyse the impact of deregulation in community pharmacy on accessibility of medicines, quality of pharmacy services and costs.

Suggested Citation

  • Vogler, Sabine & Habimana, Katharina & Arts, Danielle, 2014. "Does deregulation in community pharmacy impact accessibility of medicines, quality of pharmacy services and costs? Evidence from nine European countries," Health Policy, Elsevier, vol. 117(3), pages 311-327.
    • Handle: RePEc:eee:hepoli:v:117:y:2014:i:3:p:311-327
    DOI: 10.1016/j.healthpol.2014.06.001
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168851014001377
    Download Restriction: Full text for ScienceDirect subscribers only
    File URL: https://libkey.io/10.1016/j.healthpol.2014.06.001?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Joan-Ramon Borrell & Laura Fernández-Villadangos, 2010. "Clustering or scattering: the underlying reason for regulating distance among retail outlets," Working Papers XREAP2010-12, Xarxa de Referència en Economia Aplicada (XREAP), revised Dec 2010.
    2. Dylst, Pieter & Vulto, Arnold & Simoens, Steven, 2011. "Tendering for outpatient prescription pharmaceuticals: What can be learned from current practices in Europe?," Health Policy, Elsevier, vol. 101(2), pages 146-152, July.
    3. Morgall, Janine Marie & Almarsdóttir, Anna Birna, 1999. "No struggle, no strength: how pharmacists lost their monopoly," Social Science & Medicine, Elsevier, vol. 48(9), pages 1247-1258, May.
    4. Mossialos, Elias & Naci, Huseyin & Courtin, Emilie, 2013. "Expanding the role of community pharmacists: Policymaking in the absence of policy-relevant evidence?," Health Policy, Elsevier, vol. 111(2), pages 135-148.
    5. Kanavos, Panos G. & Vandoros, Sotiris, 2011. "Determinants of branded prescription medicine prices in OECD countries," Health Economics, Policy and Law, Cambridge University Press, vol. 6(3), pages 337-367, July.
    6. Paudyal, Vibhu & Hansford, Denise & Cunningham, Scott & Stewart, Derek, 2011. "Pharmacy assisted patient self care of minor ailments: A chronological review of UK health policy documents and key events 1997-2010," Health Policy, Elsevier, vol. 101(3), pages 253-259, August.
    7. Bernsten, Cecilia & Andersson, Karolina & Gariepy, Yves & Simoens, Steven, 2010. "A comparative analysis of remuneration models for pharmaceutical professional services," Health Policy, Elsevier, vol. 95(1), pages 1-9, April.
    8. Brekke, Kurt Richard & Holmås, Tor Helge & Straume, Odd Rune, 2013. "Margins and market shares: Pharmacy incentives for generic substitution," European Economic Review, Elsevier, vol. 61(C), pages 116-131.
    9. Leopold, Christine & Mantel-Teeuwisse, Aukje Katja & Vogler, Sabine & de Joncheere, Kees & Laing, Richard Ogilvie & Leufkens, Hubert G.M., 2013. "Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries," Health Policy, Elsevier, vol. 112(3), pages 209-216.
    10. Mossialos, Elias & Mrazek, Monique F., 2003. "The regulation of pharmacies in six countries: report prepared for the Office of Fair Trading," LSE Research Online Documents on Economics 22505, London School of Economics and Political Science, LSE Library.
    11. Paul Gorecki, 2011. "Do you believe in magic? Improving the quality of pharmacy services through restricting entry and aspirational contracts, the Irish experience," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(6), pages 521-531, December.
    12. Silcock, Jonathan & Raynor, D. K. Theo & Petty, Duncan, 2004. "The organisation and development of primary care pharmacy in the United Kingdom," Health Policy, Elsevier, vol. 67(2), pages 207-214, February.
    13. Larsen, Jakob Bjerg & Vrangbæk, Karsten & Traulsen, Janine M., 2006. "Advocacy coalitions and pharmacy policy in Denmark--Solid cores with fuzzy edges," Social Science & Medicine, Elsevier, vol. 63(1), pages 212-224, July.
    14. Schafheutle, Ellen Ingrid & Seston, Elizabeth Mary & Hassell, Karen, 2011. "Factors influencing pharmacist performance: A review of the peer-reviewed literature," Health Policy, Elsevier, vol. 102(2), pages 178-192.
    15. Bardage, Carola & Westerlund, Tommy & Barzi, Sahra & Bernsten, Cecilia, 2013. "Non-prescription medicines for pain and fever—A comparison of recommendations and counseling from staff in pharmacy and general sales stores," Health Policy, Elsevier, vol. 110(1), pages 76-83.
    16. Stargardt, Tom & Schreyögg, Jonas & Busse, Reinhard, 2007. "Pricing behaviour of pharmacies after market deregulation for OTC drugs: The case of Germany," Health Policy, Elsevier, vol. 84(1), pages 30-38, November.
    17. Lluch, Maria & Kanavos, Panos, 2010. "Impact of regulation of Community Pharmacies on efficiency, access and equity. Evidence from the UK and Spain," Health Policy, Elsevier, vol. 95(2-3), pages 245-254, May.
    18. Rudholm, Niklas, 2008. "Entry of new pharmacies in the deregulated Norwegian pharmaceuticals market--Consequences for costs and availability," Health Policy, Elsevier, vol. 87(2), pages 258-263, August.
    19. Anell, Anders, 2005. "Deregulating the pharmacy market: the case of Iceland and Norway," Health Policy, Elsevier, vol. 75(1), pages 9-17, December.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Jo, Wooyong & Nam, Hyoryung & Choi, Jeonghye, 2022. "Opening the OTC drug market: The effect of deregulation on retail pharmacy’s performance," International Journal of Research in Marketing, Elsevier, vol. 39(3), pages 847-866.
    2. Moura, Ana, 2021. "Essays in health economics," Other publications TiSEM c93abd22-fa4a-42a5-b172-d, Tilburg University, School of Economics and Management.
    3. Marcin Wiśniewski & Urszula Religioni & Piotr Merks, 2020. "Community Pharmacies in Poland—The Journey from a Deregulated to a Strictly Regulated Market," IJERPH, MDPI, vol. 17(23), pages 1-11, November.
    4. Vogler, Sabine & Zimmermann, Nina & de Joncheere, Kees, 2016. "Policy interventions related to medicines: Survey of measures taken in European countries during 2010–2015," Health Policy, Elsevier, vol. 120(12), pages 1363-1377.
    5. Bruno, Giuseppe & Cavola, Manuel & Diglio, Antonio & Elizalde, Javier & Piccolo, Carmela, 2022. "A locational analysis of deregulation policies in the Spanish retail pharmaceutical sector," Socio-Economic Planning Sciences, Elsevier, vol. 82(PA).
    6. Ana Moura & Pedro Pita Barros, 2020. "Entry and price competition in the over‐the‐counter drug market after deregulation: Evidence from Portugal," Health Economics, John Wiley & Sons, Ltd., vol. 29(8), pages 865-877, August.
    7. Gallone, Emma Luisa & Ravetto Enri, Lorenzo & Pignata, Irene & Baratta, Francesca & Brusa, Paola, 2020. "The 2017 deregulation of pharmacies in Italy: Introducing non-pharmacist ownership," Health Policy, Elsevier, vol. 124(12), pages 1281-1286.
    8. Martins, Lurdes & Queirós, Sónia, 2015. "Competition among pharmacies and the typology of services delivered: The Portuguese case," Health Policy, Elsevier, vol. 119(5), pages 640-647.
    9. Barbarisi, Ilaria & Bruno, Giuseppe & Diglio, Antonio & Elizalde, Javier & Piccolo, Carmela, 2019. "A spatial analysis to evaluate the impact of deregulation policies in the pharmacy sector: Evidence from the case of Navarre," Health Policy, Elsevier, vol. 123(11), pages 1108-1115.
    10. Håkonsen, Helle & Sundell, Karolina Andersson & Martinsson, Johan & Hedenrud, Tove, 2016. "Consumer preferences for over-the-counter drug retailers in the reregulated Swedish pharmacy market," Health Policy, Elsevier, vol. 120(3), pages 327-333.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Barbarisi, Ilaria & Bruno, Giuseppe & Diglio, Antonio & Elizalde, Javier & Piccolo, Carmela, 2019. "A spatial analysis to evaluate the impact of deregulation policies in the pharmacy sector: Evidence from the case of Navarre," Health Policy, Elsevier, vol. 123(11), pages 1108-1115.
    2. Ana Moura & Pedro Pita Barros, 2020. "Entry and price competition in the over‐the‐counter drug market after deregulation: Evidence from Portugal," Health Economics, John Wiley & Sons, Ltd., vol. 29(8), pages 865-877, August.
    3. Moura, Ana, 2021. "Essays in health economics," Other publications TiSEM c93abd22-fa4a-42a5-b172-d, Tilburg University, School of Economics and Management.
    4. Andrea Cintolesi & Andrea Riganti, 2022. "Liberalizing the opening of new pharmacies and hospitalizations," Temi di discussione (Economic working papers) 1388, Bank of Italy, Economic Research and International Relations Area.
    5. Gallone, Emma Luisa & Ravetto Enri, Lorenzo & Pignata, Irene & Baratta, Francesca & Brusa, Paola, 2020. "The 2017 deregulation of pharmacies in Italy: Introducing non-pharmacist ownership," Health Policy, Elsevier, vol. 124(12), pages 1281-1286.
    6. Lluch, Maria & Kanavos, Panos, 2010. "Impact of regulation of Community Pharmacies on efficiency, access and equity. Evidence from the UK and Spain," Health Policy, Elsevier, vol. 95(2-3), pages 245-254, May.
    7. Guhl, Dennis & Stargardt, Tom & Schneider, Udo & Fischer, Katharina E., 2016. "Dispensing behaviour of pharmacies in prescription drug markets," Health Policy, Elsevier, vol. 120(2), pages 190-197.
    8. Håkonsen, Helle & Sundell, Karolina Andersson & Martinsson, Johan & Hedenrud, Tove, 2016. "Consumer preferences for over-the-counter drug retailers in the reregulated Swedish pharmacy market," Health Policy, Elsevier, vol. 120(3), pages 327-333.
    9. Jo, Wooyong & Nam, Hyoryung & Choi, Jeonghye, 2022. "Opening the OTC drug market: The effect of deregulation on retail pharmacy’s performance," International Journal of Research in Marketing, Elsevier, vol. 39(3), pages 847-866.
    10. Vogler, Sabine & Zimmermann, Nina & de Joncheere, Kees, 2016. "Policy interventions related to medicines: Survey of measures taken in European countries during 2010–2015," Health Policy, Elsevier, vol. 120(12), pages 1363-1377.
    11. Fontrier, Anna-Maria & Gill, Jennifer & Kanavos, Panos, 2019. "International impact of external reference pricing: should national policy makers care?," LSE Research Online Documents on Economics 100929, London School of Economics and Political Science, LSE Library.
    12. Anna-Maria Fontrier & Jennifer Gill & Panos Kanavos, 2019. "International impact of external reference pricing: should national policy-makers care?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(8), pages 1147-1164, November.
    13. Gerald J. Pruckner & Thomas Schober, 2018. "Hospitals and the generic versus brand‐name prescription decision in the outpatient sector," Health Economics, John Wiley & Sons, Ltd., vol. 27(8), pages 1264-1283, August.
    14. Bruno, Giuseppe & Cavola, Manuel & Diglio, Antonio & Elizalde, Javier & Piccolo, Carmela, 2022. "A locational analysis of deregulation policies in the Spanish retail pharmaceutical sector," Socio-Economic Planning Sciences, Elsevier, vol. 82(PA).
    15. Håkonsen, Helle & Horn, Anne Marie & Toverud, Else-Lydia, 2009. "Price control as a strategy for pharmaceutical cost containment--What has been achieved in Norway in the period 1994-2004?," Health Policy, Elsevier, vol. 90(2-3), pages 277-285, May.
    16. Pierre Dubois & Morten Sæthre, 2020. "On the Effect of Parallel Trade on Manufacturers' and Retailers' Profits in the Pharmaceutical Sector," Econometrica, Econometric Society, vol. 88(6), pages 2503-2545, November.
    17. Takizawa, Osamu & Urushihara, Hisashi & Tanaka, Shiro & Kawakami, Koji, 2015. "Price difference as a predictor of the selection between brand name and generic statins in Japan," Health Policy, Elsevier, vol. 119(5), pages 612-619.
    18. Brekke, Kurt R. & Holmås, Tor Helge & Straume, Odd Rune, 2015. "Price regulation and parallel imports of pharmaceuticals," Journal of Public Economics, Elsevier, vol. 129(C), pages 92-105.
    19. Granlund, David & Sundström, David, 2018. "Physicians prescribing originals causes welfare losses," Economics Letters, Elsevier, vol. 170(C), pages 143-146.
    20. Hedenrud, T. & Håkonsen, H., 2017. "Purchase habits, use of paracetamol, and information sources on a reregulated Swedish pharmacy market: A population-based study," Health Policy, Elsevier, vol. 121(1), pages 35-41.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:117:y:2014:i:3:p:311-327. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.